Streetbeat News

Price Targets

LESL

Loop Capital analyst Garik Shmois has downgraded Leslies (NASDAQ:LESL) from Buy to Hold and lowered the price target from $16 to $6.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:21 am

AIRC

BMO Capital analyst John Kim has upgraded Apartment Income REIT (NYSE:AIRC) from Market Perform to Outperform and raised the price target from $39 to $42.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:18 am

APLS

HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Apellis Pharmaceuticals (NASDAQ:APLS) and maintained a $100 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:16 am

PRTA

HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Prothena Corp (NASDAQ:PRTA) and maintained a $90 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:15 am

IMVT

HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Immunovant (NASDAQ:IMVT) and raises the price target from $27 to $29.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:14 am

MIRM

HC Wainwright & Co. analyst Ed Arce maintains a 'Buy' rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $61 to $63.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:13 am

JANX

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Janux Therapeutics (NASDAQ:JANX) and maintained a $35 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:11 am

KPTI

HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $10 price target.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 10:10 am

TSX:ATD

Credit Suisse analyst Karen Short has upgraded Alimentation Couche-Tard from Neutral to Outperform and raised the price target from C$65 to C$85.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:51 am

ESAB

JP Morgan analyst Tami Zakaria has downgraded ESAB (NYSE:ESAB) from Overweight to Neutral, while raising the price target from $70 to $74.

Portfolio Pulse from richadhand@benzinga.com

July 18, 2023 | 9:48 am